These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37599198)

  • 1. Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.
    Ocaña Gómez MÁ; Ferrer Machín A; Vera Cabrera M; Álvarez Tosco KI; Ríos de Paz M; de Dios García MD
    Med Clin (Barc); 2024 Feb; 162(3):134-137. PubMed ID: 37599198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
    Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
    J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
    Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
    Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
    Wang CP; Young G; Thornburg CD
    Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
    Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
    Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 14. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
    Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
    Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
    Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
    Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
    Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
    Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.